WO2001008702A3 - Immunotherapie traitant les personnes infectees par le vih utilisant des vaccins apres une multi-therapie - Google Patents

Immunotherapie traitant les personnes infectees par le vih utilisant des vaccins apres une multi-therapie Download PDF

Info

Publication number
WO2001008702A3
WO2001008702A3 PCT/US2000/020641 US0020641W WO0108702A3 WO 2001008702 A3 WO2001008702 A3 WO 2001008702A3 US 0020641 W US0020641 W US 0020641W WO 0108702 A3 WO0108702 A3 WO 0108702A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunotherapy
vaccines
drug treatment
hiv infected
infected persons
Prior art date
Application number
PCT/US2000/020641
Other languages
English (en)
Other versions
WO2001008702A9 (fr
WO2001008702A2 (fr
Inventor
Genoveffa Franchini
Zdenek Hel
Gene Shearer
James Tartaglia
Janos Nacsa
Original Assignee
Us Health
Genoveffa Franchini
Zdenek Hel
Gene Shearer
James Tartaglia
Janos Nacsa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Genoveffa Franchini, Zdenek Hel, Gene Shearer, James Tartaglia, Janos Nacsa filed Critical Us Health
Priority to JP2001513432A priority Critical patent/JP2003505516A/ja
Priority to AU66128/00A priority patent/AU779494B2/en
Priority to EP00953728A priority patent/EP1198248A2/fr
Priority to CA002380018A priority patent/CA2380018A1/fr
Publication of WO2001008702A2 publication Critical patent/WO2001008702A2/fr
Publication of WO2001008702A3 publication Critical patent/WO2001008702A3/fr
Publication of WO2001008702A9 publication Critical patent/WO2001008702A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé amélioré dont l'objectif est de maintenir une réponse immuno-protectrice chez les personnes infectées par un rétro-virus après une thérapie anti-rétrovirale de haute efficacité.
PCT/US2000/020641 1999-07-28 2000-07-27 Immunotherapie traitant les personnes infectees par le vih utilisant des vaccins apres une multi-therapie WO2001008702A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001513432A JP2003505516A (ja) 1999-07-28 2000-07-27 Ｈｉｖ感染者における多薬物療法後のワクチンを用いた免疫療法
AU66128/00A AU779494B2 (en) 1999-07-28 2000-07-27 Immunotherapy in HIV infected persons using vaccines after multi-drug treatment
EP00953728A EP1198248A2 (fr) 1999-07-28 2000-07-27 Immunotherapie traitant les personnes infectees par le vih utilisant des vaccins apres une multi-therapie
CA002380018A CA2380018A1 (fr) 1999-07-28 2000-07-27 Immunotherapie traitant les personnes infectees par le vih utilisant des vaccins apres une multi-therapie

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US14624099P 1999-07-28 1999-07-28
US60/146,240 1999-07-28
US17898900P 2000-01-28 2000-01-28
US60/178,989 2000-01-28
US20044500P 2000-04-28 2000-04-28
US60/200,445 2000-04-28

Publications (3)

Publication Number Publication Date
WO2001008702A2 WO2001008702A2 (fr) 2001-02-08
WO2001008702A3 true WO2001008702A3 (fr) 2001-08-30
WO2001008702A9 WO2001008702A9 (fr) 2001-09-20

Family

ID=27386369

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/020641 WO2001008702A2 (fr) 1999-07-28 2000-07-27 Immunotherapie traitant les personnes infectees par le vih utilisant des vaccins apres une multi-therapie

Country Status (5)

Country Link
EP (1) EP1198248A2 (fr)
JP (1) JP2003505516A (fr)
AU (1) AU779494B2 (fr)
CA (1) CA2380018A1 (fr)
WO (1) WO2001008702A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001054701A1 (fr) * 2000-01-31 2001-08-02 Aventis Pasteur, S.A. Vaccination de personnes infectees par le vih apres une therapie antiretrovirale a haute activite
DE602004030369D1 (de) 2003-10-24 2011-01-13 Immunaid Pty Ltd Therapieverfahren
WO2006010106A2 (fr) * 2004-07-09 2006-01-26 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Vaccination par adn de sujets atteints d'un retrovirus et suivant un traitement
WO2008089144A2 (fr) * 2007-01-12 2008-07-24 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Protocoles améliorés de vaccination par adn
CA2763373C (fr) 2009-05-27 2018-01-09 Immunaid Pty Ltd Methodes et systemes permettant de determiner le moment prefere d'administration d'une therapie en vue de traiter des maladies
WO2018237339A1 (fr) 2017-06-22 2018-12-27 The Government Of The United States Of America As Represented By The Secretary Of The Army Vaccin contre le paludisme utilisant du plasmodium à base de nyvac
CN109300529B (zh) * 2018-09-12 2021-09-21 阿呆科技（北京）有限公司 基于人工智能和虚拟现实/增强现实的毒瘾渴求靶向干预矫治系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008539A1 (fr) * 1996-08-26 1998-03-05 Chiron Corporation Therapie de vaccination apres l'infection par le virus de l'immunodeficience humaine (vih)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008539A1 (fr) * 1996-08-26 1998-03-05 Chiron Corporation Therapie de vaccination apres l'infection par le virus de l'immunodeficience humaine (vih)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
F. GOTCH ET AL.: "Therapeutic Vaccines in HIV 1 infection", IMMUNOLOGICAL REVIEWS, vol. 170, 1999, pages 173 - 182, XP000982295 *
M. JOHN ET AL.: "Control of HIV replication by cytoxic T-lymphocyte responses", J. HIV THERAPY, vol. 4, no. 4, 1999, pages 91 - 87, XP000982254 *
R. MACGREGOR ET AL.: "First human trial of a DNA-based vaccine for treatment of HIV1 infection: safety and host response", J. INF. DIS., vol. 178, 1998, pages 92 - 100, XP000982247 *

Also Published As

Publication number Publication date
JP2003505516A (ja) 2003-02-12
EP1198248A2 (fr) 2002-04-24
AU779494B2 (en) 2005-01-27
CA2380018A1 (fr) 2001-02-08
WO2001008702A9 (fr) 2001-09-20
WO2001008702A2 (fr) 2001-02-08
AU6612800A (en) 2001-02-19

Similar Documents

Publication Publication Date Title
AU8499901A (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
WO2004096818A3 (fr) Procede et compositions pour l'identification de composes therapeutiques anti-vih
NZ546298A (en) Immunogenic composition and method of developing a vaccine based on factor H binding sites
NO20091761L (no) Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
WO2001000232A3 (fr) Vaccin
EP2130921A3 (fr) Vaccin pour la prévention et le traitement de l'infection par le VIH
WO2006085983A3 (fr) Adjuvants viraux
WO2001010456A3 (fr) Peptides bloquant les infections virales et procedes d'utilisation correspondants
WO2003059385A3 (fr) Vaccin contre le vih et procede d'utilisation
WO2001008702A3 (fr) Immunotherapie traitant les personnes infectees par le vih utilisant des vaccins apres une multi-therapie
WO2005089231A3 (fr) Activite renforcee de vaccin vih utilisant un oligonucleotide immunomodulateur de seconde generation
KR100725637B1 (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein
AU4088697A (en) Postinfection human immunodeficiency virus (hiv) vaccination therapy
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
WO1990013281A3 (fr) Procede de suppression d'une infection par l'hiv
ES2104695T3 (es) Induccion de proteccion contra una infeccion virica.
OA09037A (en) Prevention and treatement of retroviral disease.
AU2003300870A8 (en) Immunogenic mutant human immunodeficiency virus gp120 polypeptides, and methods of using same
WO2004041997A3 (fr) Regimes d'immunotherapie chez des patients atteints du vih
WO2002056902A3 (fr) Procede de combinaison permettant de traiter des infections virales
WO2004039945A3 (fr) Vaccins preventifs et therapeutiques contre le sida
AU2002343146A1 (en) Identification of cd8 epitopes from hiv-1 proteins for prevention and therapy of hiv infections
AU5061090A (en) Aids therapy
AU2001233063A1 (en) Vaccination of hiv infected persons following highly active antiretroviral therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/8, 2/8 AND 8/8, DRAWINGS, REPLACED BY NEW PAGES 1/8, 2/8 AND 8/8; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 66128/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000953728

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10048072

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 513432

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2380018

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2000953728

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 66128/00

Country of ref document: AU